1 |
ROSENWALD A, WRIGHT G, CHAN W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(25): 1937-1947.
|
2 |
BEA S. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction[J]. Blood, 2005, 106(9): 3183-3190.
|
3 |
PAVLOVA N N, ZHU J J, THOMPSON C B. The hallmarks of cancer metabolism: still emerging[J]. Cell Metab, 2022, 34(3): 355-377.
|
4 |
HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
|
5 |
CONDELLI V, CRISPO F, PIETRAFESA M, et al. HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy[J]. Cells, 2019, 8(6): 532.
|
6 |
SUN N Y, YANG M H. Metabolic reprogramming and epithelial-mesenchymal plasticity: opportunities and challenges for cancer therapy[J]. Front Oncol, 2020, 10: 792.
|
7 |
YIN G, LIANG Y, WANG Y, et al. mTOR complex 1 signalling regulates the balance between lipid synthesis and oxidation in hypoxia lymphocytes[J]. Biosci Rep, 2017, 37(1): BSR20160479.
|
8 |
KIRSCH B J, CHANG S J, BETENBAUGH M J, et al. Non-Hodgkin lymphoma metabolism[M]. Cham: Springer International Publishing, 2018.
|
9 |
PANDA M, TRIPATHI S K, BISWAL B K. SOX9: an emerging driving factor from cancer progression to drug resistance[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188517.
|
10 |
ENJUANES A, FERNÀNDEZ V, HERNÁNDEZ L, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma[J]. PLoS One, 2011, 6(5): e19736.
|
11 |
BENNETT L B, SCHNABEL J L, KELCHEN J M, et al. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma[J]. Genes Chromosom Cancer, 2009, 48(9): 828-841.
|
12 |
CHENG P F, SHAKHOVA O, WIDMER D S, et al. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma[J]. Genome Biol, 2015, 16(1): 42.
|
13 |
PASSERON T, VALENCIA J C, NAMIKI T, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid[J]. J Clin Invest, 2009, 119(4): 954-963.
|
14 |
PRÉVOSTEL C, RAMMAH-BOUAZZA C, TRAUCHESSEC H, et al. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ß-catenin signaling[J]. Oncotarget, 2016, 7(50): 82228-82243.
|
15 |
SLATTERY M L, HERRICK J S, MULLANY L E, et al. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer[J]. Genes Chromosom Cancer, 2017, 56(11): 769-787.
|
16 |
SCHMITZ R, WRIGHT G W, HUANG D W, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407.
|
17 |
LEICH E, SALAVERRIA I, BEA S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations[J]. Blood, 2009, 114(4): 826-834.
|
18 |
SOTIRIOU C, WIRAPATI P, LOI S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis[J]. J Natl Cancer Inst, 2006, 98(4): 262-272.
|
19 |
REDDY A, ZHANG J, DAVIS N S, et al. Genetic and functional drivers of diffuse large B cell lymphoma[J]. Cell, 2017, 171(2): 481-494.e15.
|
20 |
SHAFFER A L, WRIGHT G, YANG L M, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology[J]. Immunol Rev, 2006, 210: 67-85.
|
21 |
SUBRAMANIAN A, TAMAYO P, MOOTHA V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550.
|
22 |
YOSHIHARA K, SHAHMORADGOLI M, MARTÍNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612.
|
23 |
JIANG Y W, HATZI K, ELEMENTO O, et al. Enhancer profiling reveals SOX9 as a novel transcription regulator of B cell activation and DLBCL transformation[J]. Blood, 2012, 120(21): 527.
|
24 |
SHEN Y J, ZHOU J Q, NIE K, et al. Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas[J]. Blood, 2022, 139(1): 73-86.
|
25 |
GOOPTU M, WHITAKER-MENEZES D, SPRANDIO J, et al. Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma[J]. Semin Oncol, 2017, 44(3): 204-217.
|
26 |
LAM L T, WRIGHT G, DAVIS R E, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma[J]. Blood, 2008, 111(7): 3701-3713.
|
27 |
JIANG Y W, HATZI K, SHAKNOVICH R. Mechanisms of epigenetic deregulation in lymphoid neoplasms[J]. Blood, 2013, 121(21): 4271-4279.
|